Sequence : Nsp14
Total row(s): 1
Select item(s)
Key Findings
Comments
(You can add your comments too!)
Original Article
(hover to see details)
Compared to the SARS-CoV-2 reference genome (MN908947.3), the SARS-CoV-2 isolate, CHRF_nCoV19_0001/Bangladesh (accession number: MT476385), was observed to have nine mutations.
✍
 		32527780
(Microbiol Resour Announc)
PMID
32527780
Date of Publishing: 2020 Jun 11
Title Complete Genome Sequence of a Novel Coronavirus (SARS-CoV-2) Isolate from Bangladesh
Author(s) nameSaha S, Malaker R et al.
Journal Microbiol Resour Announc
Impact factor
0.88
Citation count: 18


Drugs : Nsp14
Total row(s): 5
Select item(s)
Key Findings
Comments
(You can add your comments too!)
Original Article
(hover to see details)
Different potential repurposed drugs, including, chloroquine , hydroxychloroquine, ivermectin, remdesivir, and favipiravir, were screened in the present study. Molecular docking of these drugs with different SARS-CoV-2 target proteins, including spike and membrane proteins, RdRp, nucleoproteins, viral proteases, and nsp14, was performed. Molecular dynamics simulation and MM-PBSA calculation were also conducted. Ivermectin and remdesivir were found to be the most promising drugs.
✍
 		33746908
(Front Microbiol)
PMID
33746908
Date of Publishing: 2020
Title Molecular Docking Reveals Ivermectin and Remdesivir as Potential Repurposed Drugs Against SARS-CoV-2
Author(s) name Eweas AF, Alhossary AA, Abdel-Moneim AS.
Journal Front Microbiol
Impact factor
4.19
Citation count: 14
Date of Entry 2021 Sep 5

The study showed that SARS-CoV-2 NSP14-a bifunctional enzyme ,could be a potential drug target for intervention and four drugs-Saquinavir, Hypericin, Baicalein and Bromocriptine were seen to be able to bind to the N-terminal and C-terminal domains of SARS-CoV-2 NSP 14 were seen as potential drug targets for intervention. The compounds including Saquinavir, Hypericin, Baicalein and Bromocriptine, could bind the N-terminus and C-terminus of the homology model of the SARS-CoV-2 Nsp14, providing as a candidate drug against SARS-CoV-2
✍
 		32923004
(J Pharm Anal)
PMID
32923004
Date of Publishing: 2020 Sep 7
Title Potential Treatment of Chinese and Western Medicine Targeting Nsp14 of SARS-CoV-2
Author(s) nameLiu C, Zhu X et al.
Journal J Pharm Anal
Impact factor
4.84
Citation count: 13
Date of Entry 2021 Sep 5

In-silico models of Nsp13 helicase and nsp14 were generated using comparative homology modelling. The structures were validated and then used for virtual screening of pre-existing, FDA approved antiviral drugs.This was done to verify that these drugs could be repurposed to be used against SARS-CoV-2 infection.
✍
 		32875166
(Gene Rep)
PMID
32875166
Date of Publishing: 2020 Dec
Title In silico structure modelling of SARS-CoV-2 Nsp13 helicase and Nsp14 and repurposing of FDA approved antiviral drugs as dual inhibitors
Author(s) name Gurung AB.
Journal Gene Rep
Impact factor
0.61
Citation count: 29
Date of Entry 2021 Sep 5

In the present study, the in silico models of SARS-CoV-2 nsp13 helicase and nsp14 protein were elucidated using a comparative homology modelling approach. Simeprevir (SMV), Paritaprevir (PTV) and Grazoprevir (GZR) were the common leads identified which show higher binding affinity to both nsp13 helicase and nsp14 as compared to the control inhibitors and therefore, they might be potential dual-target inhibitors.
✍
 		32875166
(Gene Rep)
PMID
32875166
Date of Publishing: 2020 Dec
Title In silico structure modelling of SARS-CoV-2 Nsp13 helicase and Nsp14 and repurposing of FDA approved antiviral drugs as dual inhibitors
Author(s) name Gurung AB.
Journal Gene Rep
Impact factor
0.61
Citation count: 29
Date of Entry 2021 Sep 5

The in silico models were further used for virtual screening of the Food and Drug Administration (FDA) approved antiviral drugs. Simeprevir (SMV), Paritaprevir (PTV) and Grazoprevir (GZR) were the common leads identified which show higher binding affinity to both nsp13 helicase and nsp14 as compared to the control inhibitors and therefore, they might be potential dual-target inhibitors.
✍
 		32875166
(Gene Rep)
PMID
32875166
Date of Publishing: 2020 Dec
Title In silico structure modelling of SARS-CoV-2 Nsp13 helicase and Nsp14 and repurposing of FDA approved antiviral drugs as dual inhibitors
Author(s) name Gurung AB.
Journal Gene Rep
Impact factor
0.61
Citation count: 29
Date of Entry 2021 Sep 5